Four-year persistence of type-specific immunity after quadrivalent human papillomavirus vaccination in HIV-infected children: Effect of a fourth dose of vaccine

Vaccine

Volumn 35, Issue 13, 2017, Pages 1712-1720

  Levin, Myron J ^a   Huang, Sharon ^b   Moscicki, Anna Barbara ^c   Song, Lin Ye ^b,d   Read, Jennifer S ^e   Meyer, William A ^f   Saah, Alfred J ^g   Richardson, Kelly ^h   Weinberg, Adriana ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^e EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

^f QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

^h University of Colorado Denver and Children s Hospital Colorado   (United States)

Author keywords

Antibody response; Human papillomavirus vaccine; Pediatric HIV infection

Indexed keywords

IMMUNOGLOBULIN G; PLACEBO; WART VIRUS VACCINE; VIRUS ANTIBODY;

ADAPTIVE IMMUNITY; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CHILD; CONTROLLED STUDY; DOSE RESPONSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOASSAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEROTYPE; VACCINATION; WART VIRUS; BLOOD; COMPLICATION; FOLLOW UP; IMMUNOLOGY; PAPILLOMAVIRUS INFECTION; SECONDARY IMMUNIZATION; TIME FACTOR;

ANTIBODIES, VIRAL; CHILD; FEMALE; FOLLOW-UP STUDIES; HIV INFECTIONS; HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION, SECONDARY; IMMUNOASSAY; MALE; PAPILLOMAVIRUS INFECTIONS; PLACEBOS; TIME FACTORS;

EID: 85013642155     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.02.021     Document Type: Article

References (39)

1. [1] Gillison, M.L., Chaturvedi, A.K., Anderson, W.F., Fakhry, C., Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma. J Clin Oncol 33:29 (2015), 3235–3242.
2. [2] Bosch, F.X., Broker, T.R., Forman, D., et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31:Suppl 7 (2013), H1–H31.
3. [3] Clifford, G., Franceschi, S., Diaz, M., Munoz, N., Villa, L.L., Chapter 3: HPV type-distribution in women with and without cervical neoplastic diseases. Vaccine 24:Suppl 3 (2006), S26–S34.
4. [4] Silverberg, M.J., Chao, C., Leyden, W.A., et al. HIV infection, immunodeficiency, viral replication, and the risk of cancer. Cancer Epidemiol, Biomarkers Prevention 20:12 (2011), 2551–2559.
5. [5] Guiguet, M., Boue, F., Cadranel, J., Lang, J.M., Rosenthal, E., Costagliola, D., Effect of immunodeficiency, HIV viral load, and antiretroviral therapy on the risk of individual malignancies (FHDH-ANRS CO4): a prospective cohort study. Lancet Oncol 10:12 (2009), 1152–1159.
6. [6] Del Mistro, A., Bertorelle, R., Franzetti, M., et al. Antiretroviral therapy and the clinical evolution of human papillomavirus-associated genital lesions in HIV-positive women. Clin Infect Dis 38:5 (2004), 737–742.
7. [7] Minkoff, H., Zhong, Y., Burk, R.D., et al. Influence of adherent and effective antiretroviral therapy use on human papillomavirus infection and squamous intraepithelial lesions in human immunodeficiency virus-positive women. J Infect Dis 201:5 (2010), 681–690.
8. [8] Adler, D.H., Kakinami, L., Modisenyane, T., et al. Increased regression and decreased incidence of human papillomavirus-related cervical lesions among HIV-infected women on HAART. Aids 26:13 (2012), 1645–1652.
9. [9] Hleyhel, M., Belot, A., Bouvier, A.M., et al. Risk of AIDS-defining cancers among HIV-1-infected patients in France between 1992 and 2009: results from the FHDH-ANRS CO4 cohort. Clin Infect Dis 57:11 (2013), 1638–1647.
10. [10] Simard, E.P., Pfeiffer, R.M., Engels, E.A., Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United States. Cancer 117:5 (2011), 1089–1096.
11. [11] Linkage to and Retention in HIV Medical Care. < http://www.cdc.gov/hiv/prevention/programs/pwp/linkage.html>; 2015 [accessed 11/02/15 2015].
12. [12] Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2014; 63(Rr-05). p. 1–30.
13. [13] Merck. Gardasil Package Insert. In: Corp. MSD, editor.; 2015. p. 28.
14. [14] Suzich, J.A., Ghim, S.J., Palmer-Hill, F.J., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 92:25 (1995), 11553–11557.
15. [15] Breitburd, F., Kirnbauer, R., Hubbert, N.L., et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 69:6 (1995), 3959–3963.
16. [16] Kjear, S.K., Nygard, M., Dillner, J., Munk, C., Marshall, B., Hansen, B.T., et al. Long-term effectiveness and safety of Gardasil in the Nordic countries. 2015, European Research Organisation on Genital Infection and Neoplasia, Sevilla, Spain Feb 4–7.
17. [17] Giacomet, V., Penagini, F., Trabattoni, D., et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 32:43 (2014), 5657–5661.
18. [18] Nygard, M., Saah, A., Munk, C., et al. Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine. Clin Vaccine Immunol 22:8 (2015), 943–948.
19. [19] Schwarz, T., Spaczynski, M., Kaufmann, A., et al. Persistence of immune responses to the HPV-16/18 AS04-adjuvanted vaccine in women aged 15–55 years and first-time modelling of antibody responses in mature women: results from an open-label 6-year follow-up study. BJOG: Int J Obstetrics Gynaecol 122:1 (2015), 107–118.
20. [20] Kahn, J.A., Xu, J., Kapogiannis, B.G., et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 57:5 (2013), 735–744.
21. [21] Toft, L., Storgaard, M., Muller, M., et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 209:8 (2014), 1165–1173.
22. [22] Toft, L., Tolstrup, M., Storgaard, M., Ostergaard, L., Sogaard, O.S., Vaccination against oncogenic human papillomavirus infection in HIV-infected populations: review of current status and future perspectives. Sexual Health 11:6 (2014), 511–523.
23. [23] Kojic, E.M., Kang, M., Cespedes, M.S., et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis, 2014.
24. [24] Kerneis, S., Launay, O., Turbelin, C., Batteux, F., Hanslik, T., Boelle, P.Y., Long-term immune responses to vaccination in HIV-infected patients: a systematic review and meta-analysis. Clin Infect Dis 58:8 (2014), 1130–1139.
25. [25] Abzug, M.J., Qin, M., Levin, M.J., et al. Immunogenicity, immunologic memory, and safety following measles revaccination in HIV-infected children receiving highly active antiretroviral therapy. J Infect Dis 206:4 (2012), 512–522.
26. [26] Siberry, G.K., Patel, K., Bellini, W.J., et al. Immunity to measles, mumps, and rubella in US children with perinatal HIV infection or perinatal HIV exposure without infection. Clin Infect Dis 61:6 (2015), 988–995.
27. [27] Levin, M.J., Moscicki, A.B., Song, L.Y., et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 55:2 (2010), 197–204.
28. [28] Dias, D., Van Doren, J., Schlottmann, S., et al. Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol 12:8 (2005), 959–969.
29. [29] Opalka, D., Lachman, C.E., MacMullen, S.A., et al. Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay. Clin Diagn Lab Immunol 10:1 (2003), 108–115.
30. [30] Opalka, D., Matys, K., Bojczuk, P., et al. Multiplexed serologic assay for nine anogenital human papillomavirus types. Clin Vaccine Immunol 17:5 (2010), 818–827.
31. [31] Brown, D.R., Garland, S.M., Ferris, D.G., et al. The humoral response to Gardasil over four years as defined by total IgG and competitive Luminex immunoassay. Hum Vaccin 7:2 (2011), 230–238.
32. [32] Ferris, D., Samakoses, R., Block, S.L., et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics 134:3 (2014), e657–e665.
33. [33] Kojic, E.M., Kang, M., Cespedes, M.S., et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 59:1 (2014), 127–135.
34. [34] Wilkin, T., Lee, J.Y., Lensing, S.Y., et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 202:8 (2010), 1246–1253.
35. [35] Brown, D., Muller, M., Sehr, P., et al. Concordance assessment between a multiplexed competitive Luminex immunoassay, a multiplexed IgG Luminex immunoassay, and a pseudovirion-based neutralization assay for detection of human papillomaviruse types 16 and 18. Vaccine 32:44 (2014), 5880–5887.
36. [36] Villa, L.L., Costa, R.L., Petta, C.A., et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol 6:5 (2005), 271–278.
37. [37] Longet, S., Schiller, J.T., Bobst, M., Jichlinski, P., Nardelli-Haefliger, D., A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 85:24 (2011), 13253–13259.
38. [38] Sutcliffe, C.G., Moss, W.J., Do children infected with HIV receiving HAART need to be revaccinated?. Lancet Infect Dis 10:9 (2010), 630–642.
39. [39] Weinberg, A., Song, L.Y., Saah, A., et al. Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children. J Infect Dis 206:8 (2012), 1309–1318.